Tag: ulcerative
Abivax provides update on strategy of combination treatment program in ulcerative colitis (UC). – 09/25/2024 at 10:15 p.m.
[ad_1] ABIVAX Press Release Abivax provides an update on the strategy of the combination treatment program in ulcerative colitis (UC) and announces early preclinical data on the combination of obefazimod…
Johnson & Johnson: Tremfya approved for ulcerative colitis – 09/12/2024 at 2:50 p.m.
[ad_1] (AOF) – Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved its Tremfya (guselkumab) product for the treatment of adults with moderately to…
J&J: positive trial for Tremfya in ulcerative colitis
[ad_1] (CercleFinance.com) – Johnson & Johnson announced the first results of a Phase 3 study of Tremfya (guselkumab) in the treatment of moderately to severely active ulcerative colitis. The study…
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
[ad_1] Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating…
Eli Lilly: FDA approves its treatment for ulcerative colitis – 10/27/2023 at 2:41 p.m.
[ad_1] (AOF) – Eli Lilly and Company announced today that the Food and Drug Administration (FDA) has approved Omvo (mirikizumab-mrkz) infusion for the treatment of moderately to severely active ulcerative…
Abivax highlights its clinical development program for obefazimod in ulcerative colitis
[ad_1] By Claude Leguilloux Published on 02/10/2023 at 6:49 p.m. Photo credit © Abivax (Boursier.com) — Abivax SA,…
Bristol Myers: Ulcerative Colitis Education Campaign
[ad_1] (CercleFinance.com) – Bristol Myers Squibb has launched Supporting You with UC, an educational campaign on ulcerative colitis (UC) with Rosie White, Patient Ambassador, Women’s World Cup commentator, former professional…
OSE Immunotherapeutics pursues clinical development in ulcerative colitis with full worldwide rights to Lusvertikimab – 05/12/2023 at 18:00
[ad_1] • Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody. • Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility…
OSE Immunotherapeutics: positive clinical results against ulcerative rectolitis – 02/22/2023 at 18:13
[ad_1] (AOF) – OSE Immunotherapeutics announces the publication in “The Journal of Immunology” of positive Phase 1 clinical results of OSE-127/S95011, an IL-7 receptor (IL-7R) antagonist, developed in partnership with…
Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. – 10/11/2022 at 6:06 p.m.
[ad_1] ABIVAX press release Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. First patient included in the United…
J&J: the promise of Stelara in ulcerative colitis
[ad_1] (CercleFinance.com) – J&J today presented final long-term (LTE) data from a Phase 3 study demonstrating the efficacy and safety of Stelara (ustekinumab) over four years of treatment in adult…
ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. – 04/08/2022 at 18:05
[ad_1] ABIVAX press release ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. The protocols for…